今日药学

2013, v.23(06) 333-336+341

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

沙格列汀对新诊断2型糖尿病患者血清炎症因子及外周血单个核细胞核因子κB活性的影响
Effects of Saxagliptin on Serum Inflammation Markers and Nuclear Factor κB Activity in Peripheral Blood Mononuclear cells in Newly Diagnosed Type 2 Diabetes Patients

张莹;张浩航;谢毅娟;孟栋栋;陈慧;刘恩;
ZHANG Ying,ZHANG Hao-hang,XIE Yi-juan,MENG Dong-dong,CHEN Hui,LIU En(Department of Endocrinology,The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510150,China)

摘要(Abstract):

目的前瞻性观察沙格列汀治疗对新诊断2型糖尿病(T2DM)患者血清炎症因子及外周血单个核细胞(PMNC)核因子κB(NF-κB)活性的影响。方法 30例新诊断T2DM患者,口服沙格列汀片治疗12周,观察治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1C)、血压、体质量、体质量指数(BMI)、血脂谱、稳态模型评估的胰岛素抵抗指数(HOMA-IR)、血清炎症因子:超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、肿瘤坏死因子(TNF-α)水平及PMNC核因子κB p65(Ser536)活性。血清炎症因子采用酶联免疫吸附法测定;PMNC NF-κB(Ser536)活性采用western blot检测。结果沙格列汀治疗12周后,空腹血糖、餐后2 h血糖、HbA1c、体质量、BMI、HOMA-IR指数较治疗前明显下降(P<0.05或0.01)。患者收缩压(SBP)、舒张压(DBP)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)较治疗前无明显变化。外周血PMNC磷酸化NF-κB p65(Ser536)水平及血清炎症因子水平均较基线明显降低(P<0.05或0.01)。协方差分析显示治疗12周时血清hs-CRP水平仍显著低于治疗前(F=5.835,P<0.05)。结论沙格列汀有效降低新诊断T2DM患者血糖,并抑制血清炎症因子水平及外周血PMNC NF-κB活性,发挥独立于降糖外的抗炎作用。
Objective To investigate the effects of saxagliptin on serum inflammation markers and nuclear factor κB(NF-κB) activity in peripheral blood mononuclear cells(PMNC) in newly diagnosed type 2 diabetes patients.Methods A total of 30 newly diagnosed type 2 diabetes patients underwent saxagliptin treatment(5 mg QD) for 12 weeks.The change of fasting plasm glucose(FPG),2 h postprandial blood glucose(2 hPPG),HbA1C,blood lipids,SBP,DBP,weight,BMI,homeostasis model assessment for insulin resistance index(HOMA-IR) were evaluated after 12 weeks treatment.Furthermore,serum levels of inflammatory cytokines: high sensitivity C reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α) were assayed by enzyme linked immunosorbent assay,phosphorylation status of NF-κB p65(Ser536) in PMNC was measured by western blot at the start(0 w) and the endpoint(12 w).Results Over the 12 weeks treatment period,FPG,2 hPPG,HbA1c,weight,BMI,and HOMA-IR were significantly decreased(P < 0.05 or 0.01).There were not significant variations of SBP,DBP,TC,TG,LDL-C,HDL-C comparing with baseline levels at 12 weeks.Serum levels of inflammatory markers and the levels of phosphorylation NF-κB P65(Ser536) significantly decreased at 12 weeks(P < 0.05 or 0.01).Covariance analysis showed that the level of serum hs-CRP was significant decreased comparing with baseline at 12 weeks(F = 5.835,P < 0.05).Conclusion Treatment with saxagliptin could effectively improved glycemic control,decrease the levels of serum markers,and inhibit NF-κB activity in PMNC in newly diagnosed type 2 diabetes patients,the anti-inflammatory effect is independent of glycemic control.

关键词(KeyWords): 2型糖尿病;炎症;沙格列汀;核因子kB
type 2 diabetes;inflammation;saxagliptin;nuclear factor κ B

Abstract:

Keywords:

基金项目(Foundation): 2012广东省药学会2型糖尿病用药研究基金(编号:2012C08)

作者(Author): 张莹;张浩航;谢毅娟;孟栋栋;陈慧;刘恩;
ZHANG Ying,ZHANG Hao-hang,XIE Yi-juan,MENG Dong-dong,CHEN Hui,LIU En(Department of Endocrinology,The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510150,China)

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享